Response to systemic therapy in fumarate hydratase–deficient renal cell carcinoma

2021 ◽  
Vol 151 ◽  
pp. 106-114
Author(s):  
Lucia Carril-Ajuria ◽  
Emeline Colomba ◽  
Luigi Cerbone ◽  
Carmen Romero-Ferreiro ◽  
Laurence Crouzet ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Systemic Therapy ◽  
Renal Cell ◽  
Fumarate Hydratase

scholarly journals 723P Response to systemic therapy in fumarate hydratase (FH) mutated papillary renal cell carcinoma (pRCC): Is there a winner?

2020 ◽  
Vol 31 ◽  
pp. S567-S568
Author(s):  
L. Carril ◽  
E. Colomba-Blameble ◽  
L. Cerbone ◽  
L. Crouzet ◽  
B. Laguerre ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Systemic Therapy ◽  
Renal Cell ◽  
Fumarate Hydratase ◽  
Papillary Renal Cell Carcinoma

No role of adjuvant systemic therapy after complete metastasectomy in metastatic renal cell carcinoma?

2007 ◽  
Vol 25 (4) ◽  
pp. 310-316 ◽  
Author(s):  
Cheol Kwak ◽  
Yong Hyun Park ◽  
Chang Wook Jeong ◽  
Sang Eun Lee ◽  
Ja Hyeon Ku
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Systemic Therapy ◽  
Renal Cell ◽  
Adjuvant Systemic Therapy

scholarly journals Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2

2021 ◽  
Vol 69 (4) ◽  
pp. 888-892
Author(s):  
Joseph I Clark ◽  
Brendan Curti ◽  
Elizabeth J Davis ◽  
Howard Kaufman ◽  
Asim Amin ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Melanoma ◽  
Systemic Therapy ◽  
Renal Cell ◽  
Interleukin 2 ◽  
Progression Free Survival ◽  
High Dose ◽  
Free Survival

High-dose interleukin-2 (HD IL-2) was approved in the 1990s after demonstrating durable complete responses (CRs) in some patients with metastatic melanoma (mM) and metastatic renal cell carcinoma (mRCC). Patients who achieve this level of disease control have also demonstrated improved survival compared with patients who progress, but limited data are available describing the long-term course. The aim of this study was to better characterize long-term survival following successful HD IL-2 treatment in patients with no subsequent systemic therapy. Eleven HD IL-2 treatment centers identified patients with survival ≥5 years after HD IL-2, with no subsequent systemic therapy. Survival was evaluated from the date of IL-2 treatment to June 2017. Treatment courses consisted of 2 1-week cycles of HD IL-2. Patients were treated with HD IL-2 alone, or HD IL-2 followed by local therapy to achieve maximal response. 100 patients are reported: 54 patients with mM and 46 patients with mRCC. Progression-free survival (PFS) after HD IL-2 ranges from 5+ years to 30+ years, with a median follow-up of 10+ years. 27 mRCC and 32 mM are alive ≥10 years after IL-2. Thus, a small subset of patients with mM and mRCC achieve long-term PFS (≥5 years) after treatment with HD IL-2 as their only systemic therapy. The ability of HD IL-2 therapy to induce prolonged PFS should be a major consideration in studies of new immunotherapy combinations for mM and mRCC.

Low-grade Oncocytic Fumarate Hydratase-deficient Renal Cell Carcinoma

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Ameer Hamza ◽  
Deepika Sirohi ◽  
Steven C. Smith ◽  
Mahul B. Amin
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Fumarate Hydratase ◽  
Low Grade

Systemic therapy for sarcomatoid renal cell carcinoma

2011 ◽  
Vol 11 (6) ◽  
pp. 913-920 ◽  
Author(s):  
Lance C Pagliaro ◽  
Nizar Tannir ◽  
Kanishka Sircar ◽  
Eric Jonasch
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Systemic Therapy ◽  
Renal Cell ◽  
Sarcomatoid Renal Cell Carcinoma

Phase II Trial Investigating Definitive Radiation Therapy in Lieu of Systemic Therapy for Oligometastatic Renal Cell Carcinoma

2021 ◽  
Author(s):  
Chad Tang ◽  
Pavlos Msaouel ◽  
Kieko Hara ◽  
Haesun Choi ◽  
Venus Le ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Radiation Therapy ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Systemic Therapy ◽  
Renal Cell ◽  
Phase Ii Trial

Systemic therapy for renal cell carcinoma

2005 ◽  
pp. 263-272
Author(s):  
Yoo-Joung Ko ◽  
Michael B. Atkins
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Systemic Therapy ◽  
Renal Cell
Sign in / Sign up

Export Citation Format

Share Document